<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Characteristics of patients with grade 3 neuroendocrine neoplasms in studies comparing grade 3 well to moderately differentiated neuroendocrine tumors and neuroendocrine carcinomas</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Characteristics of patients with grade 3 neuroendocrine neoplasms in studies comparing grade 3 well to moderately differentiated neuroendocrine tumors and neuroendocrine carcinomas</h1>
<div class="graphic"><div class="figure"><div class="ttl">Characteristics of patients with grade 3 neuroendocrine neoplasms in studies comparing grade 3 well to moderately differentiated neuroendocrine tumors and neuroendocrine carcinomas</div><div class="cntnt"><table cellspacing="0"><colgroup width="40%"></colgroup><colgroup span="2" width="30%"></colgroup> <tbody> <tr> <td class="subtitle1">Characteristic</td> <td class="subtitle1">NET G-3</td> <td class="subtitle1">NEC</td> </tr> <tr> <td>Number of patients, n (%)</td> <td class="centered">89 (23)<sup>[1,2,3,4]</sup></td> <td class="centered">298 (77)<sup>[1,2,3,4]</sup></td> </tr> <tr> <td>Distribution of patients (%)</td> <td class="centered">18 to 32<sup>[1,2,4]</sup></td> <td class="centered">68 to 79<sup>[1,2,4]</sup></td> </tr> <tr> <td>Age (median)</td> <td class="centered">52 to 56<sup>[1,4]</sup></td> <td class="centered">55 to 64<sup>[1,4]</sup></td> </tr> <tr> <td colspan="3">Primary tumor location (%)</td> </tr> <tr> <td class="indent1">Esophagus</td> <td class="centered">0<sup>[1,2]</sup></td> <td class="centered">5 to 8<sup>[1,5]</sup></td> </tr> <tr> <td class="indent1">Stomach</td> <td class="centered">8 to 24<sup>[1,2]</sup></td> <td class="centered">7 to 8<sup>[1,5]</sup></td> </tr> <tr> <td class="indent1">Pancreas</td> <td class="centered">33 to 65<sup>[1,2,3]</sup></td> <td class="centered">13 to 25<sup>[1,3,5]</sup></td> </tr> <tr> <td class="indent1">Colon-rectum</td> <td class="centered">8 to 29<sup>[1,2]</sup></td> <td class="centered">24 to 32<sup>[1,5]</sup></td> </tr> <tr> <td class="indent1">Small-bowel</td> <td class="centered">0 to 5<sup>[1,2]</sup></td> <td class="centered">3 to 5<sup>[1,5]</sup></td> </tr> <tr> <td>Functional tumors (%)</td> <td class="centered">14 to 25<sup>[1,3]</sup></td> <td class="centered">0 to 6<sup>[1,3,4,5]</sup></td> </tr> <tr> <td>Genetic syndrome</td> <td class="centered">0 to 5<sup>[3,4]</sup></td> <td class="centered">0<sup>[3,4,5]</sup></td> </tr> <tr> <td>Stage IV (%)</td> <td class="centered">62 to 100<sup>[1,3,4]</sup></td> <td class="centered">44 to 75<sup>[1,3,4]</sup></td> </tr> <tr> <td>Percentage of elevated plasma marker (CgA, NSE)</td> <td class="centered">CgA&gt;NSE<sup>[3]</sup></td> <td class="centered">NSE&gt;CgA<sup>[3]</sup></td> </tr> <tr> <td class="indent1">CgA (%)</td> <td class="centered">42<sup>[3]</sup></td> <td class="centered">31<sup>[3]</sup></td> </tr> <tr> <td class="indent1">NSE (%)</td> <td class="centered">25<sup>[3]</sup></td> <td class="centered">50<sup>[3]</sup></td> </tr> <tr> <td>Uptake on 18-FDG PET/CT (%)</td> <td class="centered">25 to 75<sup>[1,3]</sup></td> <td class="centered">19 to 89<sup>[1,3,5]</sup></td> </tr> <tr> <td>Uptake on somatostatin receptor scintigraphy (%)</td> <td class="centered">88 to 92<sup>[1,3]</sup></td> <td class="centered">40 to 50<sup>[1,3]</sup></td> </tr> <tr> <td>Ki-67 (median, %)</td> <td class="centered">21 to 40<sup>[1,2,3,4]</sup></td> <td class="centered">30 to 80<sup>[1,2,3,4,5]</sup></td> </tr> <tr> <td>Mitotic index</td> <td class="centered">8 to 17<sup>[3,4]</sup></td> <td class="centered">–</td> </tr> <tr> <td>Necrosis (%)</td> <td class="centered">42<sup>[3]</sup></td> <td class="centered">75 to 76<sup>[3,5]</sup></td> </tr> <tr> <td>Surgery of primary tumor (%)</td> <td class="centered">60 to 83<sup>[1,3]</sup></td> <td class="centered">14 to 36<sup>[1,3,5]</sup></td> </tr> <tr> <td>Overall survival in months from diagnosis</td> <td class="centered">41 to 99<sup>[1,3,4]</sup></td> <td class="centered">11 to 17<sup>[1,2,3,4,5]</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes">NET G-3: well-differentiated grade 3 neuroendocrine tumor; NEC: neuroendocrine carcinoma; CgA: chromogranin A; NSE: neuron-specific enolase; 18-FDG: 18-fluorodeoxyglucose; PET: positron emission tomography; CT: computed tomography.</div><div class="graphic_reference">References:
	<ol>
<li>Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015; 22:657.</li>
<li>Scoazec JY, Couvelard A, Monges F, et al. Well-differentiated grade 3 digestive neuroendocrine tumors: Myth or reality—The PRONETstudy group. J Clin Oncol 2012; 30(suppl):4129a.</li>
<li>Vélayoudom-Céphise, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 2013; 20:649.</li>
<li>Basturk O,Yang Z,Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39:683.</li>
<li>Walter T, Tougeron D, Baudin E, et al. Characteristics, prognosis and treatments of 294 patients with poorly differentiated neuroendocrine carcinoma: The FFCD-GTE national cohort. J Clin Oncol 2015; 33(suppl):4095a.</li>
</ol>
<p class="extra_spacing_top">From: Coriat R, Walter T, Terris B, et al. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist 2016; 21:1191. <a href="https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2015-0476" target="_blank">https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2015-0476</a>. Copyright © 2016 Society for Translational Oncology. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href="/cdn-cgi/l/email-protection#15"><span class="__cf_email__" data-cfemail="473722352a2e34342e28293407302e2b223e6924282a">[email protected]</span></a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href="http://onlinelibrary.wiley.com" target="_blank">http://onlinelibrary.wiley.com</a>).</p></div><div id="graphicVersion">Graphic 111374 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
